Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 17/20 | 0.75 |
| ▸ | PIK3CA | P42336 | 14/20 | 0.75 |
| ▸ | PIK3C2A | O00443 | 2/20 | 0.75 |
| ▸ | PIK3C2B | O00750 | 2/20 | 0.75 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.58 |
| ▸ | PIK3CG | P48736 | 5/20 | 0.58 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.58 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | FECH | P22830 | 1/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | GSK3A | P49840 | 1/20 | 0.58 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.58 |
| ▸ | MELK | Q14680 | 1/20 | 0.58 |
| ▸ | MYLK3 | Q32MK0 | 1/20 | 0.58 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.58 |
| ▸ | TP53RK | Q96S44 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 12/20 | 0.56 |
| ▸ | ATR | Q13535 | 5/20 | 0.56 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994007 | 0.91 | MTOR (0.63) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL928744 | 0.85 | MTOR (0.76) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL927518 | 0.85 | MTOR (1.00) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL928267 | 0.84 | MTOR (0.76) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL9905395 | 0.83 | MTOR (0.59) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL9902791 | 0.79 | MTOR (0.59) | MTORPIK3CAPIK3CDPIK3CBPIK3CG | |
| SCHEMBL927498 | 0.79 | MTOR (0.68) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL994354 | 0.79 | MTOR (0.61) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL2068363 | 0.79 | MTOR (0.62) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD | |
| SCHEMBL9905041 | 0.78 | MTOR (0.79) | MTORPIK3CAPIK3C2APIK3C2BPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | claimed |
| US-7994170-B2 | 1,3-dihydro-imidazo[4,5-C]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2011-08-09 | — | — | US | claimed |
| EP-2292617-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors | Novartis AG (CH) | 2011-03-09 | — | — | EP | claimed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | claimed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | claimed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | claimed |
| EP-1888578-A2 | IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS | Novartis AG (CH) | 2008-02-20 | — | — | EP | claimed |
| WO-2006122806-A2 | 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-11-23 | — | — | WO | claimed |
| US-9370508-B2 | Imidazoquinolines as dual lipid kinase and mTOR inhibitors | NOVARTIS AG (CH) | 2016-06-21 | — | — | US | disclosed |
| EP-2624831-A1 | PHARMACEUTICAL COMBINATIONS | Novartis AG (CH) | 2013-08-14 | — | — | EP | disclosed |
| US-20130178479-A1 | PHARMACEUTICAL COMBINATIONS | NOVARTIS AG (CH) | 2013-07-11 | — | — | US | disclosed |
| US-8431592-B2 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20120282252-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | NOVARTIS AG (CH) | 2012-11-08 | — | — | US | disclosed |
| EP-2270008-B1 | 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors | NOVARTIS AG (CH) | 2012-10-03 | — | — | EP | disclosed |
| EP-2270008-A1 | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| US-20100105696-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | NOVARTIS AG (CH) | 2010-04-29 | — | — | US | disclosed |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2010-03-04 | — | — | US | disclosed |
| US-7667039-B2 | 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors | NOVARTIS AG (CH) | 2010-02-23 | — | — | US | disclosed |
| WO-2009118324-A1 | 5IMIDAZOQUINOLINES AND PYRIMIDINE DERIVATIVES AS POTENT MODULATORS OF VEGF-DRIVEN ANGIOGENIC PROCESSES | NOVARTIS AG (CH) | 2009-10-01 | — | — | WO | disclosed |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | NOVARTIS AG (CH) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105696-A1 | IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND mTOR INHIBITORS | MTOR, ULK1, RICTOR | MTOR 1/4885PIK3CA 34/4885PIK3C2A 19/4885 |
| US-20100056558-A1 | 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3C2A 12/4885 |
| US-20130178479-A1 | PHARMACEUTICAL COMBINATIONS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3CA 3/4885PIK3C2A 7/4885 |
| US-20120282252-A1 | 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes | KDR, FLT4, TEK | MTOR 2286/4885PIK3CA 1091/4885PIK3C2A 2258/4885 |
| US-20080194579-A1 | 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors | PDPK1, PI4KA, PIP4K2A | MTOR 89/4885PIK3CA 8/4885PIK3C2A 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.